Evidence map›Paper›PMID 40897521›Full record

Trial reportArthritis care & research2026

Exploring Patients' Profiles Associated With the Resolution of Acute Calcium Pyrophosphate Arthritis Treated With Colchicine and Prednisone: Post Hoc Analysis of a Randomized Controlled Trial.

Tristan Pascart, Laurène Norberciak, Pascal Richette, Pierre Robinet, Aurore Pacaud, Gauthier Marchasson, Thibault Rabin, Hélène Luraschi, Pierre Maciejasz, Anne-France Georgel and 5 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03128905 (Colchicine or Prednisone for the Treatment of Acute Calcium Pyrophosphate Deposition), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03128905 phase3completednot on this map

Colchicine or Prednisone for the Treatment of Acute Calcium Pyrophosphate Deposition (CPPD) Arthritis: Open-label, Randomized, Multicenter, Equivalence Trial of Efficacy and Safety

TypeinterventionalSponsorLille Catholic UniversityRan2018 to 2022Enrolled111ConditionsChondrocalcinosisArmsColchicine opocalcium 1mg, Prednisone : Cortancyl 20mg
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Tristan PascartLille Catholic University, Saint-Philibert Hospital, Lille, France.ORCID 0000-0002-8395-826X
Laurène NorberciakLille Catholic University, Saint-Philibert Hospital, Lille, France.
Pascal RichetteUniversité de Paris, INSERM, UMR-S 1132 BIOSCAR AP-HP, Lariboisière Hospital, Paris, France.ORCID 0000-0003-2132-4074
Pierre RobinetLille Catholic University, Saint-Philibert Hospital, Lille, France.
Aurore PacaudLille Catholic University, Saint-Philibert Hospital, Lille, France.
Gauthier MarchassonLille Catholic University, Saint-Philibert Hospital, Lille, France.
Thibault RabinLille Catholic University, Saint-Philibert Hospital, Lille, France.
Hélène LuraschiLille Catholic University, Saint-Philibert Hospital, Lille, France.
Pierre MaciejaszLille Catholic University, Saint-Vincent-de-Paul Hospital, Lille, France.
Anne-France GeorgelLille Catholic University, Saint-Philibert Hospital, Lille, France.
Augustin LatourteUniversité de Paris, INSERM, UMR-S 1132 BIOSCAR AP-HP, Lariboisière Hospital, Paris, France.ORCID 0000-0002-1087-7768
Hang-Korng EaUniversité de Paris, INSERM, UMR-S 1132 BIOSCAR AP-HP, Lariboisière Hospital, Paris, France.
Sébastien OttavianiUniversité Paris Cité, Hôpital Bichat-Claude Bernard, Paris, France.
Charlotte JauffretLille Catholic University, Saint-Philibert Hospital, Lille, France.
Vincent DucoulombierLille Catholic University, Saint-Philibert Hospital, Lille, France.

Funding

Programme Hospitalier de Recherche Clinique 16.02
6 · The paper itself

Abstract

objectiveThe objective was to identify factors determining acute arthritis resolution and safety with colchicine and prednisone in acute calcium pyrophosphate (CPP) crystal arthritis.

methodsWe conducted a post hoc analysis of the COLCHICORT trial, which compared colchicine and prednisone for the treatment of acute CPP crystal arthritis, using a composite outcome of secondary endpoints of the primary analysis. Factors associated with the sustained arthritis resolution with prednisone or colchicine treatment on day three, and the occurrence of gastrointestinal adverse events (AEs) with colchicine, were examined. Two different machine-learning approaches were used to identify independent factors associated with the efficacy outcome: multiple logistic regressions and a decision tree were used.

resultsIn total, 43 of 89 (48.3%) of participants were considered definite responders. In univariable analysis, definitive responders were more often hospitalized for stroke (9 of 43; P = 0.04), had an age ≥80 years old (39 of 43; P = 0.045), and were dyslipidemic (25 of 43; P = 0.03), whereas poor responders were more commonly hospitalized to manage the acute arthritis episode (22 of 43; P < 0.001) In multiple logistic regression, acute arthritis of the wrists (odds ratio [OR] 4.06, 95% confidence interval [CI] 1.21-15.50.85) were associated with arthritis resolution on day three, whereas randomization in the colchicine arm (OR 0.31, 95% CI 0.11-0.83) and diuretic use (OR 0.23, 95% CI 0.097-0.95) were associated with a poor treatment response. Hospital admission for acute arthritis, C-reactive protein levels, and estimated glomerular filtration rate were decision tree nodes selected as crucial for predicting definitive flare resolution. Three candidate variables were identified in the multiple logistic regression model explaining the occurrence of gastrointestinal AEs with colchicine: male sex (OR 0.33, 95% CI 0.07-1.29) and diabetes (OR 0.24, 95% CI 0.030-1.24) seemed protective, whereas statin use (OR 3.54, 95% CI 0.83-18.82) seemed associated with their occurrence.

conclusionThis study identified factors associated with the definitive response to colchicine and prednisone treatment in acute CPP crystal arthritis. Colchicine was associated with poorer efficacy and was impacted by a dual effect on its safety and efficacy by medications and associated conditions.

Indexed as

ChondrocalcinosisColchicinePrednisoneAcute DiseaseAdultAgedAged, 80 and overDrug Therapy, CombinationFemaleGlucocorticoidsHumansMaleMiddle AgedTreatment OutcomeColchicineGlucocorticoidsPrednisone

Identifiers

PMID40897521
PMCPMC13034091

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.